Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

 
• By Mandy Jackson

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

Samit Hirawat
Samit Hirawat was named CMO at BMS last year • Source: Bristol Myers Squibb

More from Clinical Trials

More from R&D